<DOC>
	<DOCNO>NCT01647945</DOCNO>
	<brief_summary>Mutations bone morphogenetic protein receptor 2 ( BMPR2 ) present &gt; 80 % familial ~20 % sporadic pulmonary arterial hypertension ( PAH ) patient . Furthermore dysfunctional BMP signal general feature pulmonary hypertension even non-familial PAH . We therefore hypothesized increase BMP signal might prevent reverse disease . We screen &gt; 3500 FDA approve drug propensity increase BMP signal find FK506 ( Tacrolimus ) strong activator BMP signaling . Tacrolimus restore normal function pulmonary artery endothelial cell , prevent reversed experimental PAH mouse rat . Given Tacrolimus already FDA approve know side-effect profile , ideal candidate drug use patient pulmonary arterial hypertension . The aims trial : 1 . Establish Safety FK506 patient PAH . 2 . Evaluate Efficacy FK506 PAH 3 . Identify ideal candidate future FK506 phase III clinical trial .</brief_summary>
	<brief_title>FK506 ( Tacrolimus ) Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Study Design : Randomized , placebo-controlled , four arm clinical trial . Sample Size : 10 subject arm , Total enrollment = 40 patient . 1 . 10 patient : FK-506 blood level : 3 - 5 ng/ml 2 . 10 patient : FK-506 blood level : 2 - 3 ng/ml 3 . 10 patient : FK-506 level : &lt; 2.0 ng/ml 4 . 10 patient : Placebo Study Duration : 16 week Primary Endpoints : 1 ) Safety low-dose FK506 PAH Secondary Objectives/Endpoints : 1 . Combined Clinical Events/Time Clinical Worsening @ 16 week : - All cause mortality - Transplantation - Atrial septostomy - Need escalation therapy deem site investigator - Worsening NYHA/WHO classification least 1 point . - Hospitalization right heart failure . 2 . Change 6MWD 16 week 3 . Change NT-Pro-BNP 16 week 4 . Change Uric Acid 16 week 5 . Change DLCO 16 week 6 . Change novel RV parameter transthoracic echocardiography : Change RV size , RA size , RV function , TAPSE , RVSP</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Age ≥ 18 &lt; 70 year 2 . Diagnosis WHO Group I Pulmonary Arterial Hypertension ( PAH ) ( Idiopathic ( I ) PAH , Heritable PAH ( include Hereditary Hemorrhagic Telangiectasia ) , Associated ( A ) PAH ( include collagen vascular disorder , drugs+toxins exposure , congenital heart disease , portopulmonary disease ) . 3 . Stable active PAH treatment include prostacycline phosphodiesterase inhibitor endothelin antagonist Ambrisentan alone combination ( stability define : &lt; 10 % change 6MWD , change NYHA class , hospitalization addition PAH therapy least 3 month ) . 4 . Previous Right Heart Catheterization document : 1 . Mean PAP ≥ 25 mmHg . 2 . Pulmonary capillary wedge pressure &lt; 15 mmHg . 3 . Pulmonary Vascular Resistance ≥ 3.0 Wood unit 240 dynes/sec/cm5 5. WHO functional class I IV judge investigator . 1. WHO Group II V Pulmonary Hypertension . 2 . Current prior experimental PAH treatment within last 6 month ( include limit tyrosine kinase inhibitor , rhokinase inhibitor , cGMP modulators ) . 3 . Current active treatment dual endothelin receptor antagonist bosentan . 4 . TLC &lt; 60 % predict ; TLC b/w 60 70 % predict , high resolution compute tomography must available exclude significant interstitial lung disease . 5 . FEV1 / FVC &lt; 70 % predict FEV1 &lt; 60 % predict 6 . Significant leftsided heart disease ( base screen Echocardiogram ) : 1 . Significant aortic mitral valve disease 2 . Diastolic dysfunction ≥ Grade II 3 . LV systolic function &lt; 45 % 4 . Pericardial constriction 5 . Restrictive cardiomyopathy 6 . Significant coronary disease demonstrable ischemia . 7 . Chronic renal insufficiency define estimate creatinine clearance &lt; 30 ml/min ( MDRD equation ) . 8 . Current atrial arrhythmia optimal control . 9 . Uncontrolled systemic hypertension : SBP &gt; 160 mm DBP &gt; 100mm 10 . Severe hypotension : SBP &lt; 80 mmHg . 11 . Pregnant breastfeeding . 12 . Psychiatric , addictive , disorder compromise patient 's ability provide inform consent , follow study protocol , adhere treatment instruction . 13 . Active cyclosporine use . 14 . Known allergy hypersensitivity FK506 . 15 . Planned initiation cardiac pulmonary rehabilitation period study . 16 . Human Immunodeficiency Virus infection . 17 . Moderate severe hepatic dysfunction Pugh score &gt; 10 . 18 . Hyperkalemia define Potassium &gt; 5.1 mEq/L screening . 19 . Known active infection require antibiotic , antifungal , antiviral therapy . 20 . Comorbid condition would impair patient 's exercise performance ability ass WHO functional class , include limited chronic lowback pain peripheral musculoskeletal problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PAH WHO group 1</keyword>
</DOC>